Sernova (TSE:SVA) has released an update.
Sernova Corp reports significant progress in its ongoing Phase I/II clinical trial for Type 1 Diabetes, with 7 patients achieving sustained insulin independence and control of blood sugar levels using the company’s proprietary Cell Pouch System™. The trial also saw the completion of enrollment for its second cohort, indicating the potential of this technology as a transformative treatment for Type 1 Diabetes. The company is optimistic about the Cell Pouch’s ability to improve patient outcomes and plans to release further trial results later in the year.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
